Open AccessConcise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble Factors
Author(s) -
Lee Jae W.,
Fang Xiaohui,
Krasnodembskaya Anna,
Howard James P.,
Matthay Michael A.
Publication year - 2011
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.643
Subject(s) - paracrine signalling , ards , mesenchymal stem cell , biology , lung , stem cell , stem cell therapy , immunology , inflammation , acute respiratory distress , bioinformatics , intensive care medicine , medicine , microbiology and biotechnology , receptor
Morbidity and mortality have declined only modestly in patients with clinical acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the pathophysiology. Current treatment remains primarily supportive with lung‐protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in preclinical models have not yet been translated to effective clinical treatment options. Consequently, further research in translational therapies is needed. Cell‐based therapy with mesenchymal stem cells (MSCs) is one attractive new therapeutic approach. MSCs have the capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. This review will focus on recent studies, which support the potential therapeutic use of MSCs in ALI/ARDS, with an emphasis on the role of paracrine soluble factors. STEM CELLS 2011;29:913–919